GlaxoSmithKline PLC ADR (GSK) - Cash Flow Conversion Efficiency
Based on the latest financial reports, GlaxoSmithKline PLC ADR (GSK) has a cash flow conversion efficiency ratio of 0.127x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($2.04 Billion) by net assets ($15.99 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
GlaxoSmithKline PLC ADR - Cash Flow Conversion Efficiency Trend (1990–2025)
This chart illustrates how GlaxoSmithKline PLC ADR's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read total liabilities of GlaxoSmithKline PLC ADR for a breakdown of total debt and financial obligations.
GlaxoSmithKline PLC ADR Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of GlaxoSmithKline PLC ADR ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Sanofi
MX:SNYN
|
0.048x |
|
Parker-Hannifin Corporation
NYSE:PH
|
0.060x |
|
FAST RETAIL.CO.SP.HDR 1
F:FR7H
|
N/A |
|
China Life Insurance Co Ltd A
SHG:601628
|
0.225x |
|
Intuit Inc
NASDAQ:INTU
|
0.033x |
|
Accenture plc
NYSE:ACN
|
0.052x |
|
FAST RETAIL. CO. ADR 1/10
F:FR70
|
N/A |
|
Starbucks Corporation
NASDAQ:SBUX
|
-0.191x |
Annual Cash Flow Conversion Efficiency for GlaxoSmithKline PLC ADR (1990–2025)
The table below shows the annual cash flow conversion efficiency of GlaxoSmithKline PLC ADR from 1990 to 2025. For the full company profile with market capitalisation and key ratios, see market value of GlaxoSmithKline PLC ADR.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $15.99 Billion | $7.14 Billion | 0.447x | -10.83% |
| 2024-12-31 | $13.09 Billion | $6.55 Billion | 0.501x | +3.53% |
| 2023-12-31 | $16.31 Billion | $7.89 Billion | 0.484x | -34.02% |
| 2022-12-31 | $10.10 Billion | $7.40 Billion | 0.733x | +166.55% |
| 2021-12-31 | $28.91 Billion | $7.95 Billion | 0.275x | -7.30% |
| 2020-12-31 | $28.44 Billion | $8.44 Billion | 0.297x | -10.01% |
| 2019-12-31 | $24.32 Billion | $8.02 Billion | 0.330x | -85.62% |
| 2018-12-31 | $3.67 Billion | $8.42 Billion | 2.293x | +15.66% |
| 2017-12-31 | $3.49 Billion | $6.92 Billion | 1.983x | +51.46% |
| 2016-12-31 | $4.96 Billion | $6.50 Billion | 1.309x | +352.40% |
| 2015-12-31 | $8.88 Billion | $2.57 Billion | 0.289x | -72.41% |
| 2014-12-31 | $4.94 Billion | $5.18 Billion | 1.049x | +13.43% |
| 2013-12-31 | $7.81 Billion | $7.22 Billion | 0.924x | +42.57% |
| 2012-12-31 | $6.75 Billion | $4.38 Billion | 0.648x | -8.42% |
| 2011-12-31 | $8.83 Billion | $6.25 Billion | 0.708x | +1.52% |
| 2010-12-31 | $9.74 Billion | $6.80 Billion | 0.697x | -4.45% |
| 2009-12-31 | $10.74 Billion | $7.84 Billion | 0.730x | -16.95% |
| 2008-12-31 | $8.32 Billion | $7.31 Billion | 0.879x | +50.31% |
| 2007-12-31 | $9.91 Billion | $5.79 Billion | 0.585x | +42.54% |
| 2006-12-31 | $9.65 Billion | $3.96 Billion | 0.410x | -44.42% |
| 2005-12-31 | $7.57 Billion | $5.59 Billion | 0.738x | -8.08% |
| 2004-12-31 | $5.94 Billion | $4.77 Billion | 0.803x | +39.91% |
| 2003-12-31 | $8.45 Billion | $4.85 Billion | 0.574x | +38.56% |
| 2002-12-31 | $7.39 Billion | $3.06 Billion | 0.414x | -24.54% |
| 2001-12-31 | $8.40 Billion | $4.61 Billion | 0.549x | +165.41% |
| 2000-12-31 | $8.96 Billion | $1.85 Billion | 0.207x | +29.48% |
| 1999-12-31 | $3.19 Billion | $510.00 Million | 0.160x | +7.83% |
| 1998-12-31 | $2.77 Billion | $410.00 Million | 0.148x | -54.48% |
| 1997-12-31 | $1.89 Billion | $615.00 Million | 0.325x | -51.44% |
| 1996-12-31 | $1.27 Billion | $849.00 Million | 0.670x | -88.17% |
| 1995-12-31 | $221.00 Million | $1.25 Billion | 5.665x | +32.94% |
| 1994-12-31 | $574.69 Million | $2.45 Billion | 4.261x | +1983.79% |
| 1993-12-31 | $5.15 Billion | $1.05 Billion | 0.205x | +2.74% |
| 1992-12-31 | $4.66 Billion | $927.00 Million | 0.199x | +10.25% |
| 1991-12-31 | $3.64 Billion | $657.00 Million | 0.181x | -3.65% |
| 1990-12-31 | $3.28 Billion | $615.00 Million | 0.187x | -- |
About GlaxoSmithKline PLC ADR
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, infl… Read more